digistain(@digistain) 's Twitter Profile Photo

To all our supporters this year, all the patients & clinicians we have worked with, and the many we plan to help in the future… …we wish you all a wonderful festive season and a healthy happy 2024.

To all our supporters this year, all the patients & clinicians we have worked with, and the many we plan to help in the future… …we wish you all a wonderful festive season and a healthy happy 2024.
account_circle
digistain(@digistain) 's Twitter Profile Photo

Technology to overcome the time and cost challenges associated with traditional breast cancer recurrence risk testing. Find out more here digistain.co.uk

Technology to overcome the time and cost challenges associated with traditional breast cancer recurrence risk testing. Find out more here digistain.co.uk
#breastcancer #innovation
account_circle
EIT Health France(@EIThealth_FR) 's Twitter Profile Photo

9 startups dont 2 françaises atteignent la finale de l’EIT Health Catapult ! 👇

Domaine :
🇬🇧Celex Oncology
🇳🇱Pan Cancer T
🇫🇷POLYGON Therapeutics

Domaine :
🇸🇪Acorai
🇬🇧digistain
🇩🇪Dymium
🇫🇷Five Lives
🇪🇸nen
🇦🇹Saphenus

Finale les 5-6 juin à Munich

9 startups dont 2 françaises atteignent la finale de l’EIT Health Catapult ! 👇

Domaine #LifeScience:
🇬🇧Celex Oncology
🇳🇱Pan Cancer T
🇫🇷POLYGON Therapeutics

Domaine #HealthTech:
🇸🇪@Acorai_Official
🇬🇧@digistain
🇩🇪Dymium
🇫🇷Five Lives
🇪🇸nen
🇦🇹Saphenus

Finale les 5-6 juin à Munich
account_circle
Joiston Pereira(@JoistonPereira) 's Twitter Profile Photo

Glad to announce on digistain will be joining the UK🇬🇧-India 🇮🇳Healthcare Trade Mission (13-17 Feb).

Digistain’s MHRAgovuk approved patented breast cancer grading & prognosis solution is used for hormone receptor positivity risk profiling.

Glad to announce on #worldcancerday @digistain will be joining the UK🇬🇧-India 🇮🇳Healthcare Trade Mission (13-17 Feb). 

Digistain’s @MHRAgovuk approved patented breast cancer grading & prognosis solution is used for hormone receptor positivity risk profiling. 
 #cancerday2023
account_circle
Carlo Palmieri(@cancermedic) 's Twitter Profile Photo

Complexly novel way to assess risk of recurrence in ER+/HER2- early breast cancer using mid-infrared spectrometer digistain It’s simple,quick & can be done locally. First data using Nottinghan series, shows it can separate patients into low vs high risk. More studies underway.

Complexly novel way to assess risk of recurrence in ER+/HER2- early breast cancer using mid-infrared spectrometer @digistain It’s simple,quick & can be done locally. First data using Nottinghan series, shows it can separate patients into low vs high risk. More studies underway.
account_circle
EIT Health Ireland-UK(@EITHealth_IRLUK) 's Twitter Profile Photo

Meet digistain , a game-changer in cancer diagnosis and a semi-finalist in this year’s EIT Health Catapult competition.

They aim to eliminate breast cancer care inequalities by transforming the speed, cost and accuracy of recurrence risk prediction.

lnkd.in/esV2Hj_b

Meet @digistain , a game-changer in cancer diagnosis and a semi-finalist in this year’s @EITHealth Catapult competition. 

They aim to eliminate breast cancer care inequalities by transforming the speed, cost and accuracy of recurrence risk prediction. 

lnkd.in/esV2Hj_b
account_circle